These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22081583)

  • 1. Estimating the annual number of false negative cystic fibrosis newborn screening tests.
    Fritz A; Farrell P
    Pediatr Pulmonol; 2012 Feb; 47(2):207-8. PubMed ID: 22081583
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations.
    Hammond KB; Abman SH; Sokol RJ; Accurso FJ
    N Engl J Med; 1991 Sep; 325(11):769-74. PubMed ID: 1870650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
    Sontag MK; Hammond KB; Zielenski J; Wagener JS; Accurso FJ
    J Pediatr; 2005 Sep; 147(3 Suppl):S83-8. PubMed ID: 16202790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newborn screening for cystic fibrosis is complicated by age-related decline in immunoreactive trypsinogen levels.
    Rock MJ; Mischler EH; Farrell PM; Wei LJ; Bruns WT; Hassemer DJ; Laessig RH
    Pediatrics; 1990 Jun; 85(6):1001-7. PubMed ID: 2187173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The French nationwide cystic fibrosis newborn screening program: strategy and results].
    Munck A; Roussey M
    Arch Pediatr; 2008 Jun; 15 Suppl 1():S1-6. PubMed ID: 18822253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positive neonatal screening for cystic fibrosis in neonates with renal failure.
    Oosterveld MJ; Schilperoort JV; Lilien MR; Arets HG
    Thorax; 2010 Jul; 65(7):652-3. PubMed ID: 20627926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clarification of laboratory and clinical variables that influence cystic fibrosis newborn screening with initial analysis of immunoreactive trypsinogen.
    Kloosterboer M; Hoffman G; Rock M; Gershan W; Laxova A; Li Z; Farrell PM
    Pediatrics; 2009 Feb; 123(2):e338-46. PubMed ID: 19171585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neonatal screening for cystic fibrosis].
    Tellería Orriols JJ; Alonso Ramos MJ; Garrote Adrados JA; Fernández Carvajal I; Blanco Quirós A
    An Esp Pediatr; 2002 Jul; 57(1):60-5. PubMed ID: 12139895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. False negative cystic fibrosis newborn screen.
    Collaco JM; Panny SR; Hamosh A; Mogayzel PJ
    Clin Pediatr (Phila); 2010 Mar; 49(3):214-6. PubMed ID: 20164071
    [No Abstract]   [Full Text] [Related]  

  • 10. [Implementation of the neonatal cystic fibrosis screening program in Switzerland: beginning January 2011].
    Mornand A; Barben J; Hafen G
    Rev Med Suisse; 2011 Feb; 7(283):456, 458-60. PubMed ID: 21452515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variation in immunoreactive trypsinogen concentrations among Michigan newborns and implications for cystic fibrosis newborn screening.
    Korzeniewski SJ; Young WI; Hawkins HC; Cavanagh K; Nasr SZ; Langbo C; Teneyck KR; Grosse SD; Kleyn M; Grigorescu V
    Pediatr Pulmonol; 2011 Feb; 46(2):125-30. PubMed ID: 20848586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study.
    Vernooij-van Langen AM; Loeber JG; Elvers B; Triepels RH; Gille JJ; Van der Ploeg CP; Reijntjens S; Dompeling E; Dankert-Roelse JE;
    Thorax; 2012 Apr; 67(4):289-95. PubMed ID: 22271776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Value of neonatal screening for cystic fibrosis. Evaluation of a neonatal screening program including 34,522 neonates (author's transl)].
    Cristol P; Des Georges M; Levy A; Sahuc P
    Sem Hop; 1982 Feb; 58(8):499-55. PubMed ID: 6278637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the costs of diagnosing cystic fibrosis with a newborn screening program.
    Lee DS; Rosenberg MA; Peterson A; Makholm L; Hoffman G; Laessig RH; Farrell PM
    J Pediatr; 2003 Jun; 142(6):617-23. PubMed ID: 12838188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new cystic fibrosis newborn screening algorithm: IRT/IRT1 upward arrow/DNA.
    Sontag MK; Wright D; Beebe J; Accurso FJ; Sagel SD
    J Pediatr; 2009 Nov; 155(5):618-22. PubMed ID: 19540513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What drives neonatal screening programs?
    Holtzman NA
    N Engl J Med; 1991 Sep; 325(11):802-4. PubMed ID: 1870654
    [No Abstract]   [Full Text] [Related]  

  • 17. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm.
    Parad RB; Comeau AM
    J Pediatr; 2005 Sep; 147(3 Suppl):S78-82. PubMed ID: 16202789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Newborn screening for cystic fibrosis, a clinical geneticist perspective].
    Sanak M
    Przegl Lek; 2011; 68(1):14-6. PubMed ID: 21563437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neonatal screening for cystic fibrosis].
    Lucidi V; Lelli A; Castro M; Bella S; Ciuffetti C; Ravet P; Orrù M; Angeloni U; Angeloni P
    Pediatr Med Chir; 1994; 16(5):445-8. PubMed ID: 7885953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group.
    Farrell PM; Kosorok MR; Laxova A; Shen G; Koscik RE; Bruns WT; Splaingard M; Mischler EH
    N Engl J Med; 1997 Oct; 337(14):963-9. PubMed ID: 9395429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.